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A prospective analysis of olfaction was performed in 21 patients receiving cisplatin. A reduction in olfactory function was noted in
only one patient. Hearing impairment was documented in nine patients, none of whom had impaired sense of smell. We conclude
that cisplatin has no major deleterious effect on olfactory function at doses which cause hearing impairment.
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Disorders associated with a decreased taste sensation may result in
a deleterious effect on quality of life and may contribute to reduced
food intake and malnutrition, thereby increasing the side effects of
cancer therapy (Comeau et al, 2001).
Cisplatin neurotoxicity (Peltier and Russell, 2002) and ototoxi-
city (Schaefer et al, 1985; Bartoshuk, 1995) are widely recognised,
with hearing impairment reported in up to 81% of patients treated
with high-dose cisplatin (Laurell and Jungnelius, 1990). Cisplatin
has been reported to have a deleterious effect on taste sensation
(Wickham et al, 1999). We therefore hypothesised that high-dose
cisplatin might result in a reduced sense of smell. Olfactory cells
are bipolar neurons that undergo constant regeneration with an
average turnover time of about 30 days (Schiffman, 1997). The
direct application of cisplatin to the olfactory apparatus in a
guinea-pig model caused atrophy of the olfactory epithelium,
olfactory nerve and olfactory bulb (Zhou and Lin, 1995). Several
subjective reports have noted that up to 52% of patients receiving
cisplatin were aware of smell changes (Rhodes et al, 1994;
Wickham et al, 1999; de Graeff et al, 2000; Schiffman and Graham,
2000), but only one previous study has prospectively addressed the
issue of olfactory alterations after chemotherapy (Ovesen et al,
1991). We therefore carried out a prospective study incorporating
objective qualitative tests of olfaction in order to test our
hypothesis that cisplatin will result in an impaired sense of smell
in cancer patients. In addition, we investigated other factors that
may influence olfactory function. These included disease status,
smoking history and serum zinc levels. Auditory function tests
were carried out as a control parameter for cisplatin toxicity.
PATIENTS AND METHODS
Patients over 18 years of age admitted to the oncology department
at the Chaim Sheba Medical Center for intravenous chemotherapy
including cisplatin at a dose of at least 75mgm
 2 per cycle and
who were planned to receive a cumulative dose of cisplatin greater
than 200mgm
 2 were recruited to this study. Exclusion criteria
included a history of chronic rhino-sinusitis or sino-nasal surgery,
a tumour involving olfactory pathways or brain, and prior
irradiation therapy to the head and neck region. The study was
approved by the hospital ethics (Helsinki) committee and all
participating patients gave written informed consent before
inclusion in this study. All patients had normal blood count and
renal function (24h creatinine clearance 450mlmin
 1) and
received standard hydration (42500ml) and a standard intrave-
nous antiemetic protocol (8mg Ondansetron or 3mg Granisetron
together with 8mg dexamethasone).
The study group comprised 21 consecutive patients (13 males
and eight females) admitted between July 2003 and June 2004 for
the treatment of a variety of primary tumours (upper digestive
tract, lung, cervix, unknown primary carcinoma, malignant
melanoma or metastatic seminoma). The patients were treated
with standard departmental chemotherapy protocols for their
tumour types, all of which included cisplatin in doses of
75mgm
 2cycle
 1 or more combined with either 5-fluorouracil,
or with etoposide (VP-16) (with or without bleomycin), or with
temozolomide according to tumour type. The patients’ ages ranged
from 28 to 78 years (mean 53.6 years). At enrolment, a detailed
history was obtained, including demographic details, smoking
history, tumour type and co-morbid pathology.
METHODS
Olfactory function was tested before beginning chemotherapy
(baseline), and after each course of cisplatin. The final olfactory
assessment was performed at least 3 weeks after the last course of
cisplatin.
Olfaction was assessed using the ‘Sniffin’ Sticks
s’ kit consisting
of odorants in felt-tip pens (Wolfensberger et al, 2000). For odour
presentation, the opened pens are positioned approximately 2cm
in front of both nostrils (all patients were tested bilaterally) for
3–4s at intervals of 30s. A patient has to choose one of four items
that best describes the presented odour. The number of correctly
chosen items gives the olfactory status score.
The sign test and Wilcoxon signed rank test for matched
samples were used to estimate the statistical significance of the
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schanges. The Spearman rank correlation was calculated for
estimation of the relationship between the changes and the
number of measurements.
Standard audiometry monitoring was performed. Serum zinc
levels were measured in 14 patients.
RESULTS
In all, 21 patients completed the planned chemotherapeutic
treatment. They received one to six (mean 3.4) cycles of
chemotherapy, with cumulative doses of cisplatin ranging from
180 to 945mg and a mean cumulative dose of 525mg
(330mgm
 2). In one patient, a 60% decrease in olfaction was
noted after the third course of treatment and a cumulative dose of
cisplatin of 225mgm
 2. No decrease in olfactory function was
found in 20 (95.3%) patients and in fact 10 patients had a final
olfaction score that was higher than the pretreatment score. These
score changes were statistically significant (P¼0.0117 for the sign
test and P¼0.0322 for the Wilcoxon test). However, the rank
correlation between the number of measurements and the
improvement in olfactory function in these patients (ro¼0.505,
P¼0.014) suggests that this may be a result of learning effect.
Hearing impairment was documented in nine patients (bilateral
high tone sensori-neural hearing loss in all cases). The single
patient whose olfaction decreased had no hearing loss.
Of 14 patients whose serum zinc levels were analysed, it was
normal or increased in 12, according to normal ranges (75–
120mcgdl
 1). In two patients reduced levels of zinc were seen after
the second and third chemotherapeutic course, respectively.
Neither of these patients had impaired olfaction. In one of them
hearing impairment was registered. The patient whose olfactory
function deteriorated had normal serum zinc levels.
DISCUSSION
Cisplatin-induced olfactory deterioration is a possible conse-
quence of the recognised neurotoxicity of this agent (Bartoshuk,
1995; Comeau et al, 2001; Peltier and Russell, 2002). An additional
factor that could aggravate this effect is zinc deficiency, which has
been found to be associated with taste dysfunction (Heyneman,
1996). The specific role of zinc in the control of taste and smell is
unknown, but it is functionally involved at several levels of cellular
organisation (Ripamonti et al, 1998). Cisplatin has been reported
to increase urinary zinc excretion and reduce serum zinc levels
(Sweeney et al, 1989). Oral zinc administration has been shown to
hasten recovery of the sense of taste in patients undergoing
radiotherapy for head and neck cancer (Ripamonti et al, 1998). It
was therefore suggested that cisplatin might impair olfaction not
only by its neurotoxic effect, but also indirectly via depletion of
serum zinc levels.
Until recently, it was difficult to accurately measure olfactory
status due to a lack of accurate and reproducible tools. ‘Sniffin’
sticks’ is a noninvasive odour identification kit with odours of
varying consistencies, which has been validated and used in several
studies investigating the olfactory apparatus (Hummel et al, 2001)
and has demonstrated deterioration in olfactory threshold in
patients receiving radiotherapy for nasopharyngeal cancer (Ho
et al, 2002).
Though subjective olfactory function impairment has been
reported by a considerable number of cisplatin-treated patients
(Rhodes et al, 1994; de Graeff et al, 2000), the only objective study
thus far failed to show such an effect. Ovesen measured olfactory
thresholds in 22 patients prior to and 2–3 months after treatment
with several chemotherapeutic agents. They did not find statisti-
cally significant changes in olfaction although it should be noted
that in this study the testing was performed with binary dilutions
of a single odorant (Ovesen et al, 1991).
The results of our study performed with a more sophisticated
test of olfactory function confirm the lack of an early effect of
cisplatin on olfactory function. A decrease in olfaction was noted
in one patient (4.7%) in our study. The cumulative dose of
cisplatin given to this patient was relatively low and chemotherapy
was discontinued after three cycles because of disease progression.
Our results are in accordance with the results of Ovesen et al, who
also failed to demonstrate impaired olfaction following treatment
with cisplatin. A quality-of-life questionnaire-based study reported
a subjective change in sense of smell in 26% of patients following
high-dose chemotherapy and bone marrow transplantation,
although more patients reported an increase in smell sensation
rather than a decrease (Epstein et al, 2002).
In our study, the incidence of hearing impairment, an accepted
indicator of cisplatin neurotoxicity, was 48%, which is comparable
with results of similar studies (Blakley and Myers, 1993).
The single patient whose olfactory status did deteriorate had
no detectable hearing impairment. Serum zinc levels were
monitored in 14 (67%) patients in the study. Only two (12%) of
them showed a tendency toward hypozincaemia. The single patient
with impaired olfaction had normal zinc levels after cisplatin
treatment.
Our study has several limitations. It is a single-blind study and
did not include a control group of patients who were not receiving
cisplatin through the comparable period of the study. The ‘Sniffin’
Sticks
s’ kit used allows assessment of odour differentiation acuity
rather than olfactory thresholds evaluation. Minimal and maximal
limits of olfactory performance measured with this kit do not allow
recording of further improvement of olfactory function in patients
with maximal score or further deterioration in patients with
minimal score. The fact that in 10 of 21 patients the final olfaction
score was higher than the pretreatment score can possibly be
explained by the patients learning the odours used in the test over
time. The rank correlation between the number of measurements
and the improvement in measured olfaction supports the
contention that this may be a result of learning effect. Despite
these limitations to our study, the lack of a decrease in olfactory
function in all 10 patients who developed cisplatin-induced
hearing reduction indicates that cisplatin has no significant
deleterious effect on olfactory function.
CONCLUSIONS
Based on several subjective reports, cisplatin has often been cited
as a cause of altered olfactory perception. The result of our study
and the single other prospective study reported (Ovesen et al,
1991) is that cisplatin has no measurable effect on the sense of
smell. We conclude that there is no early negative effect of cisplatin
on olfaction. Further, long-term studies are warranted in order to
evaluate the delayed effects of cisplatin on olfaction.
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